Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Ther Methods Clin Dev
Autors principals: Castella, Maria, Boronat, Anna, Martín-Ibáñez, Raquel, Rodríguez, Vanina, Suñé, Guillermo, Caballero, Miguel, Marzal, Berta, Pérez-Amill, Lorena, Martín-Antonio, Beatriz, Castaño, Julio, Bueno, Clara, Balagué, Olga, González-Navarro, Europa Azucena, Serra-Pages, Carles, Engel, Pablo, Vilella, Ramon, Benitez-Ribas, Daniel, Ortiz-Maldonado, Valentín, Cid, Joan, Tabera, Jaime, Canals, Josep M., Lozano, Miquel, Baumann, Tycho, Vilarrodona, Anna, Trias, Esteve, Campo, Elías, Menendez, Pablo, Urbano-Ispizua, Álvaro, Yagüe, Jordi, Pérez-Galán, Patricia, Rives, Susana, Delgado, Julio, Juan, Manel
Format: Artigo
Idioma:Inglês
Publicat: American Society of Gene & Cell Therapy 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6319086/
https://ncbi.nlm.nih.gov/pubmed/30623002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2018.11.010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars